<DOC>
	<DOCNO>NCT00156286</DOCNO>
	<brief_summary>This study involve treat initially combination drug call irinotecan cisplatin ( induction therapy ) , follow treatment drug call Gleevec ( maintenance therapy ) . The main purpose study determine type treatment delay growth tumor , long . The investigator also want find tumor affect solely induction therapy irinotecan cisplatin , side-effects occur Gleevec maintenance therapy use , treatment ( induction follow maintenance therapy ) improve duration survival</brief_summary>
	<brief_title>Gleevec Maintenance Therapy After Induction Irinotecan Cisplatin Patients With C-Kit Positive Extensive SCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Histologically cytologically confirm extensivestage SCLC , ckitpositive immunohistochemistry . Extensivestage define disease extend beyond one hemithorax regional lymph node ( ipsilateral contralateral hilar , mediastinal supraclavicular lymph node ) , cytologically positive pleural effusion . 2 . No prior chemotherapy SCLC . Patients start therapy cisplatin irinotecan , dosage mention protocol , prior registration register trial do within 21 day start first cycle chemotherapy . Prior palliative radiation therapy allow long radiation complete least 2 week start protocol therapy . 3 . At least 18 year age 4 . At least one unidimensionally measurable lesion evaluable outside field prior radiation therapy . 5 . Adequate organ function 6 . Patients must sign informed consent detail investigational nature study accord institutional federal guideline . 1 . Symptomatic history untreated brain leptomeningeal metastasis . Treated patient neurologically stable 2 week completion appropriate therapy . 2 . Previous concurrent malignancy , exception adequately treat squamous cell basal cell carcinoma skin , situ carcinoma cervix , malignancy treat clinical remission 3 year . 3 . Major surgery radiation therapy within 2 week enrollment . 4 . Peripheral neuropathy NCI grade great 2 . 5 . Symptomatic edema etiology . 6 . Therapeutic anticoagulation warfarin . Patients eligible change warfarin low molecular weight heparin heparin least 2 week prior start Gleevec . 7 . Serious concomitant medical illness , include , limited , uncontrolled congestive cardiac failure , uncontrolled angina , myocardial infarction and/or stroke within 3 month , HIV infection . 8 . Acute chronic liver disease ( e.g. , chronic active hepatitis , cirrhosis ) . 9 . History dementia , active psychiatric disorder condition , consider treat physician impair patient 's ability take oral pill daily basis comply protocol requirement . 10 . Pregnant lactating female . All premenopausal perimenopausal woman negative urine pregnancy test prior enrollment . All patient , men woman , reproductive potential agree use effective contraceptive method duration trial 3 month discontinuation study treatment . 11 . Patients participate investigational agent study take part trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>